The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials

The authors aimed to evaluate the effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) in improving survival outcomes for patients with newly diagnosed and recurrent ovarian cancer. Their meta-analysis of seven randomized trials found that HIPEC significantly enhanced progression-free survival and overall survival in newly diagnosed cases treated with interval cytoreductive surgery, while showing no significant benefits in recurrent cases. The study suggests that HIPEC, particularly with a 90-minute protocol, is beneficial for newly diagnosed ovarian cancer without a substantial increase in severe adverse effects, but its role in recurrent disease remains unclear.